

The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica

Sarah L. Mackie¹, Helen Twohig², Lorna M Neill³, Eileen Harrison⁴, Beverley Shea⁵, Rachel J Black⁶, Tanaz A Kermani⁷, Peter A Merkel⁸, Christian Mallen⁹, Frank Buttgereit¹⁰, Chetan Mukhtyar¹¹, Lee S Simon¹², Catherine L Hill^{6,13} on behalf of the OMERACT PMR Working Group.

Key indexing terms:

Polymyalgia rheumatica, outcomes, OMERACT

1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
2. Academic Unit of Primary Medical Care, University of Sheffield, Sheffield, UK
3. PMR-GCA Scotland
4. PMR and GCA North East
5. Ottawa Hospital Research Institute and School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Canada K1H 8L6
6. Discipline of Medicine, The University of Adelaide, Adelaide, Australia
7. Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA
8. Division of Rheumatology and Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA
9. Primary Care and Health Sciences, Keele University, Keele, UK
10. Department of Rheumatology and Clinical Immunology, Charite University Hospital Berlin, Germany
11. Norfolk and Norwich University Hospital, Norwich, UK
12. SDG LLC, Cambridge, Massachusetts, USA
13. Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia

Grant support: NIHR Clinician Scientist Fellowship to Sarah Mackie; unrestricted grant from Horizon Pharmaceuticals. Rachel Black is the recipient of an Australian Rheumatology Association OMERACT Fellowship 2016.

SL Mackie BM BCh PhD, Associate Clinical Professor and Honorary Consultant Rheumatologist, University of Leeds s.l.mackie@leeds.ac.uk

H Twohig MBChB, General Practitioner, Academic Unit of Primary Medical Care, University of Sheffield h.twohig@sheffield.ac.uk

LM Neill, BSc, PMR-GCA Scotland and OMERACT Patient Research Partner, gdneill@gotadsl.co.uk

E Harrison, BSc, PMR and GCA North East and OMERACT Patient Research Partner, harrisoneileen@gmail.com

B Shea, PhD, Senior Methodologist and Adjunct Professor, University of Ottawa
bevshea@uottawa.ca

R Black MBBS, Consultant Rheumatologist and Clinical Lecturer, Discipline of
Medicine, The University of Adelaide Rachel.Black2@sa.gov.au

TA Kermani MD MS, Assistant Clinical Professor, Division of Rheumatology, UCLA,
TKermani@mednet.ucla.edu

PA Merkel, MD MPH, Professor of Medicine and Epidemiology, Division of
Rheumatology and Department of Biostatistics and Epidemiology, University of
Pennsylvania pmerkel@upenn.edu

CD Mallen PhD, NIHR Research Professor in General Practice, Arthritis Research UK
Primary Care Centre, Research Institute for Primary Care, Keele University
c.d.mallen@keele.ac.uk

F Buttgereit MD, Professor of Rheumatology, Department of Rheumatology and
Clinical Immunology, Charite University Hospital Berlin frank.buttgereit@charite.de

C Mukhtyar MD, Consultant Rheumatologist, Norfolk and Norwich University
Hospital, UK CHETAN.MUKHTYAR@nnuh.nhs.uk

L S Simon MD, Principal, SDG LLC, Cambridge, Massachusetts lssconsult@aol.com

C Hill MD, Clinical Professor and Consultant Rheumatologist, Discipline of Medicine,
The University of Adelaide Catherine.Hill@sa.gov.au

Corresponding author and reprint requests to Sarah Mackie, Leeds Institute of
Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, West
Yorkshire LS7 4SA, United Kingdom

Running footer: *PMR core domain set*
2351 words

Abstract

Background.

To inform development of a core domain set for outcome measures for clinical trials in polymyalgia rheumatica (PMR), we previously conducted patient consultations, a systematic review, a Delphi study and two qualitative studies.

Methods.

Domains identified by 70% or more of physicians and/or patients in the Delphi study were selected. The conceptual framework derived from the two qualitative research studies helped inform the meaning of each domain and its relationship to the others. The draft core domain set was refined by further discussion with patients and physicians who had participated in the Delphi study. At OMERACT 2016 the domains were discussed and prioritized by eight Breakout Groups. Formal voting took place at the end of the Workshop and in the final Plenary.

Results.

93% of voters in the final plenary agreed that the inner core of domains considered mandatory for clinical trials of PMR should comprise: laboratory markers of systemic inflammation, pain, stiffness, and physical function. Patient global and fatigue were considered “important” but not mandatory (outer core). The research agenda included: psychological impact, weakness, physical activity, participation, sleep, imaging, and health-related quality of life.

Conclusions.

This core domain set was considered sufficiently well-defined that the next step will be to apply the OMERACT Filter 2.0 Instrument Selection Algorithm to select candidate instruments for a subsequent “deeper dive” into the data. This will allow instruments to be mapped onto each of our core domains in order to derive a core outcome set for PMR.

Introduction

Polymyalgia rheumatica (PMR) is an inflammatory disease of older people, causing pain and stiffness of the shoulders and hip girdles(1). The prevalence of PMR is about 1% in people over 50 years in the US (2) and UK (3). Many patients with PMR are managed by general practitioners / family physicians rather than rheumatologists(4, 5). The mainstay of treatment is long-term therapy with glucocorticoids. This treatment approach has the potential for toxicity, depending on glucocorticoid dose and patient-specific factors such as age(6, 7). The most recent PMR treatment guidelines conditionally recommend early addition of methotrexate to glucocorticoids, especially if there are risk factors for relapse, for prolonged therapy, or for glucocorticoid-related adverse effects(8). A stronger recommendation could not be made because the published randomized trials were small, with partly contradictory results. No high-quality evidence was identified evaluating any other potential glucocorticoid-sparing agent(8). A systematic review of domains and instruments in 35 PMR trials and longitudinal observational studies, conducted by the OMERACT PMR Working Group, found inconsistency and poor clarity of outcome measures recorded for PMR(9). The poor evidence base for management of PMR urgently requires improvement. Our objective is to produce guidance to researchers on a core outcome set for PMR: the minimal common set of outcome measurement instruments that should always be included in clinical trials of PMR, whether conducted in the community or specialist setting. Prior to recommending measurement instruments, it is necessary to define a core domain set of what it is that must be measured.

Here we report on the process that was used to generate a core domain set for clinical trials of PMR based on a combination of stakeholder engagement, evidence synthesis, qualitative research, and a Delphi study. This is the first-ever core domain set developed for clinical trials of PMR and has had strong patient involvement throughout. This core domain set will inform selection and validation of instruments to be used in clinical trials of PMR. It will also be relevant to design of observational studies and studies to develop a PMR-specific patient-reported outcome measure. This report represents the culmination of a process reported in two prior OMERACT Special Interest Group reports(10, 11), work leading up to and during the 2016 OMERACT Workshop on PMR, and original primary research already published in full elsewhere (9, 12, 13). The new matter in this report includes a description of the methods and results of the Delphi survey and the process that was used to bring together multiple different sources of information (patient consultations, systematic literature review, one Delphi survey, two qualitative studies, further patient and clinician consultation to refine the draft core domain set, and a Workshop at OMERACT 2016) to arrive at a core domain set for PMR that was endorsed by 93% of voters in the final conference plenary, as well as highlighting areas that required further definition, such as Psychological Impact.

What is new since the last conference report:

- Report of the methods and results of the Delphi survey of patients and clinicians
- Report of the process that was used to bring together multiple different sources of information (patient consultations, systematic literature review, Delphi study, two qualitative studies, further patient and clinician consultation, and a Workshop at OMERACT 2016)
- A core domain set for PMR endorsed by 93% of voters in the final conference plenary
- A prioritized research agenda based on areas of continuing uncertainty or insufficient evidence, including psychological impact

Scoping the problem

We intend our core outcome set to apply to interventional research studies conducted in any setting, with a study duration of at least three months and typically one year(14). The domains selected would also be relevant to design of observational studies, which could be much larger or of longer duration.(15) We began by consulting stakeholders on all outcomes they considered important for patients diagnosed with PMR; in later phases we asked them to focus on clinical trials in order to give the context necessary for the prioritization of domains for a parsimonious core domain set.

Patient involvement

Clinical management decisions relating to patients diagnosed with PMR are highly dependent on the patient's symptoms; acute-phase laboratory markers are used as supportive evidence(1). Defining what these symptoms are is therefore essential. Some of the patient research partners, including both co-authors of the current report, involved over the life of this project were deeply involved in patient support groups (telephone and/or internet forums). Patient support groups were also helpful in identifying participants for our Delphi study.

Patient consultations

To inform the scope of the problem we started with a patient-driven consultation exercise(11). A convenience sample of 104 English-speaking patients with PMR under the care of rheumatologists from the UK and elsewhere in Europe were included and a modified nominal group technique was used, involving group discussions about three prespecified topics (symptoms, diagnosis and treatment), followed by sorting of cards to identify each patient's "top ten" items for each topic. We reported these within the ICF framework of impairments, disability, and participation(11).

Comparing outcome of patient consultations with systematic review findings

Using the OMERACT Filter 2.0 Framework(16) we identified that outcomes reported in trials and observational studies of patient with PMR(9) did not always map well onto the messages emerging from our patient consultations (Table 1). For example, patients preferred "stiffness" to "morning stiffness" and also considered fatigue to be important. Patients preferred to describe their

experience of PMR in terms of its impact on activities such as getting out of bed, turning over in bed, getting up from the sofa or toilet, driving, picking items up from the floor, opening doors, walking, and dressing. They found the symptoms themselves hard to describe. The psychological impact of their condition was also mentioned. We noted that research studies had no standard definitions of key PMR symptoms; for example, in the literature it was frequently unclear exactly how patients had been asked about their pain severity, where that pain was and what period of time was being asked about(9). Similarly the precise definition and meaning of “morning stiffness” in PMR appeared unclear in many published studies(9). There was also no standard method employed for reporting outcomes related to the burden of glucocorticoid therapy. Even the main daily dose and cumulative dose of glucocorticoid were not always well-reported.

Analysis of composite outcomes used in studies of PMR(17) showed that many included domains from both Pathophysiological Manifestations (acute phase markers and/or ability to elevate upper limbs) and Life Impact (symptom or patient-reported component). Although none of these composite outcomes has yet been completely validated according to the OMERACT Filter, they are informative regarding what aspects of PMR are considered important by experts in PMR.

Delphi study

In order to understand the differing perspectives of patients and physicians in prioritizing outcomes, we carried out a three-round Delphi study(10). We were advised by the National Research Ethics Service that ethical approval was not required. Although the disease (PMR) and its life impact may well be similar across countries, there are differences in the language used to describe this by patients. Whereas international English-speaking physicians are accustomed to using a common dialect (medical English) for accessing research studies and educational material, this is not necessarily the case for patients. To avoid potential misunderstanding arising from international differences in English vocabulary and usage, for our Delphi study we chose to recruit English-speaking patients from the UK.

The Delphi study started with two groups: patients (from UK patient organisations, self-identifying as diagnosed with PMR) and clinicians. 55 patients with PMR took part. Of these, 46 completed round 2 and 34 completed round 3. 85 clinicians with an interest in PMR were identified from Pubmed searches and attendance at relevant sessions at international meetings (ACR, EULAR). 60 clinicians replied to round 1, 55 to round 2 and 53 to round 3. Among the 60 clinicians in round 1, 21 were from UK, 28 from elsewhere in Europe, 6 from North America, and 5 from Australasia. Self-reported expertise, other than clinical rheumatology and an interest in PMR, was: clinical trials research (26), outcomes research (19), epidemiology (11), qualitative research (5), general practice (5), and the allied health professions(2). Potential domains were grouped using the framework of Filter 2.0 (including “Resource Use” but omitting “Death” from the list, since the latter is always mandatory in Filter 2.0) and informed by the prior patient consultations and systematic review findings.

In order to avoid influence of the patients on the clinicians or vice versa, rounds 1 and 2 were conducted separately. However, in order to identify areas of consensus and disagreement, we started with the same list of domains for everyone, using plain language rather than rheumatology jargon wherever possible. In round 1, respondents selected their “top ten” domains and had the option of adding any further domains to generate an expanded list. In round 2, each group was presented with the domains selected by >70% of respondents and were asked which other domains from the expanded list they considered essential for a core domain set for clinical trials of PMR. Those new domains selected by >70% of respondents in round 2 were added to that group’s list. The 70% cut off, while arbitrary, is conventional for Delphi studies as well as being the usual level of consensus for OMERACT voting. Because of the variety of potential domains that seemed more relevant to glucocorticoid exposure, a separate item for glucocorticoid-related adverse effect was added in round 2. Results of rounds 1 and 2 are given in Table 2. In round 3, the domains finally selected by both groups were presented and opinions sought on the combined domain set. Free-text feedback at each stage allowed participants to give their reasoning for including or not including particular domains. A total of 91% of respondents (85% clinicians, 97% patients) agreed with the draft core domain set, with the major divergence of opinion appearing to be in relation to different perceptions of the meaning of the words “muscle weakness” in medical English versus everyday English. It also became clear that “morning stiffness [duration]”, a technical diagnostic term in rheumatology, is a different domain from “stiffness” as conceptualised by patients, who said that stiffness severity (rather than duration) was of key importance.

Qualitative research on core PMR symptoms of pain and stiffness

A qualitative study (13) explored in more depth what stiffness means to patients, and how it relates to pain. 50 patients with a clear, rheumatologist-confirmed diagnosis of PMR took part in eight focus groups; this convenience sample was recruited from three UK rheumatology clinics. Pain and stiffness usually represented related but different symptoms. Pain (“ache, hurt”) was an unpleasant experience, not necessarily related to movement. Stiffness (the experience of being prevented from movement) had profound consequences for daily functioning. Many patients suggested that measuring physical function would be the best way to measure stiffness itself. Fatigue was seen as separate from either pain or stiffness, but having impact on the broader experience of PMR.

Qualitative research on the broader patient experience in PMR

A second qualitative study explored the broader experience of PMR for patients treated in the community (12). The analysis of this study proceeded in parallel with the activities of the PMR Working Group and discussions before its publication informed the group’s thinking. At OMERACT 2016 the methodology and findings were presented. Based on the conceptual framework derived from the qualitative data we added the domain ‘Psychological Impact’, which had emerged as a surprisingly strong theme from the interviews.

Domain prioritization

OMERACT presents domains using an “onion” diagram of three nested circles, with the domains in the innermost circle (“Inner Core”) being mandatory for every clinical trial; the middle circle is labeled “Important” and the outer circle “Research Agenda”(18). The Inner Core should contain at least one domain chosen from each of the Core Areas including Pathophysiological Manifestations and Life Impact. It was recognized that the list of candidate domains derived from the Delphi was likely too long to be suitable for an Inner Core. Therefore, in the run-up to OMERACT 2016, informal email engagement was carried out with patients and physicians who had participated in the Delphi study. A long-list of domains that might be eligible for the Inner Core was proposed, based on all of the evidence presented above, and feedback was invited. This resulted in removal of the domain of Physician Global as several physicians told us that they felt Physician Global to be a composite construct, principally comprising information from laboratory markers of inflammation and the patient global (both of which were already on the long-list of domains). There were also questions about whether the underlying construct of Physician Global would genuinely be a scalar quantity or whether it was better conceptualized as a binary decision to escalate or reduce glucocorticoid dose, closer to the concept of relapse/remission. As the only remaining “Pathophysiological Manifestations” domain was Systemic Inflammation (Laboratory Blood Tests), the breakout discussions at the OMERACT Workshop focused on the Life Impact aspect of PMR.

Breakout group discussions

In order to encourage the discussion at breakout groups to draw on authentic patient experience, quotes from the qualitative interview were printed onto cards, and we handed a randomly-chosen card to each individual participant in the Breakout Group. Breakout Group Facilitators then asked their groups to prioritise the domains, based on the results of the research described and cited in the pre-conference reading, the work presented in the Plenary, and the quotes they had on their individual cards.

Synthesis of advice from breakout groups

Consistent with the conceptual model that emerged from both qualitative studies, pain/ache, stiffness and physical function were prioritized highly by the breakout groups as regards Life Impact (Table 3).

Feedback from several breakout groups suggested that including Patient Global in addition to the “top three” life impact domains could introduce redundancy, since the qualitative data suggested such a strong overlap with physical function. Given the strong drive towards parsimony for this patient population, therefore, and given the lack of quantitative evidence to confirm or refute this suggestion, it was decided to provisionally rank this as “important” rather than “core”.

Psychological Impact was felt to be important but to require further clarification of its meaning before inclusion in the Inner Core. The two candidate “psychological” domains that were drawn from the literature and entered into the Delphi (Mood problems – low or “high”, Anxiety) reached the 70% threshold

in the patient arm of the Delphi study. However, the qualitative study data suggested that Psychological Impact goes beyond the clinical constructs of simple anxiety or mood disturbance and in fact describes complex, evolving and pervasive effects on patients' psychological state (for example, pre-diagnosis fears, relief at diagnosis followed by an ongoing sense of loss(12); and "PMR always on one's mind"(13)) that are not necessarily well-described by the clinical constructs of anxiety or depression or indeed well-understood by clinicians. This was identified as a clear priority for further patient-centred research, perhaps with a view to developing a PMR- specific patient-reported outcome measure encompassing the psychological impact relating to this disease.

Breakout groups also advised adding to the research agenda the following domains: Participation, Weakness, Glucocorticoid exposure, Physical activity, Sleep, Imaging, and Health-related Quality of Life. Some attendees also pointed out that some caution was required in the interpretation of the qualitative research because of the limited geographical area (UK) from which the participants were drawn.

The Workshop concluded with a formal vote on whether each of our long-list domains should be included in the "inner core" for clinical trials (Table 3). Based on these votes, which was also in line with the results of our qualitative studies, we entered the three Life Impact domains plus Systemic Inflammation (Laboratory Blood Tests) into the proposed Inner Core.

Summary

Based on all the quantitative and qualitative feedback received during the whole process, an "onion" diagram (Figure 1) was presented at the Final Plenary session of the conference. 93% of voters agreed with the final proposed Inner Core Domain Set (laboratory markers of systemic inflammation, pain, stiffness, physical function).

Future work

Although there was substantial agreement on the inner core domains, the limitations of the voting procedure should be acknowledged; the system of one vote per attendee meant that clinicians' votes outnumbered patients' votes. The process also identified a substantial list of potential outcomes requiring further research in PMR. It will also be important to conduct further work with patients outside the UK, including non-English speakers, to assess generalizability of the concepts presented here. The OMERACT Handbook describes the next step, which will be to apply the OMERACT Filter 2.0 Instrument Selection Algorithm (the "eyeball test"), a systematic screening process to select candidate instruments for a subsequent "deeper dive" into the data to finally determine whether each selected instrument should be included in the core outcome set.

Acknowledgements

We thank all the patients who so generously contributed in so many ways to all stages of this project. We also thank all the members of the rheumatology research community who have provided important feedback during the latter stages of the development of this core domain set. Those not already listed as co-authors, include (but are not limited to): Toby Helliwell, Elisabeth Brouwer, Joanna Robson, Christina Duftner, Mar Pujades-Rodriguez, Pereira da Silva, Maria Cid, Lyn March and Maarten Boers. John Kirwan provided invaluable leadership, expertise and guidance, including in the design of the Delphi.

Financial support for patient travel was received from the OMERACT charity DINORA, which received an unrestricted grant from Horizon Pharmaceuticals. This work represents independent research conducted by the authors and does not necessarily represent the views of the NIHR, the UK NHS or the UK Department of Health.

Figure Legends

Figure 1. Proposed Core Domain Set for polymyalgia rheumatica clinical trials.

This “onion” figure uses nested circles with the innermost circle denoting the Inner Core (mandatory to measure in all clinical trials of PMR), the middle circle denoting Important outcomes (strongly recommended to measure in PMR), and the outer circle denoting the Research Agenda (those domains that require further investigation in PMR). “Mandatory” domains (bottom right) are those that should be reported by default in all clinical trials of any condition. The proposed contextual factors (bottom left) are suggestions we received regarding possible contextual factors and represent hypothesized factors only. HR-QoL: health-related quality of life.

References

1. Mackie SL, Mallen CD. Polymyalgia rheumatica. *BMJ* 2013;347:f6937.
2. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis Rheum.* 2008;58:26-35
3. Hayward RA, Rathod T, Muller S, Hider SL, Roddy E, Mallen CD. Association of polymyalgia rheumatica with socioeconomic status in primary care: a cross-sectional observational study. *Arthritis Care Res.* 2014;66:956-60.
4. Barraclough K, Liddell WG, du Toit J, Foy C, Dasgupta B, Thomas M, et al. Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. *Fam Pract.* 2008;25:328-33.
5. Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Use of physician services in a population-based cohort of patients with polymyalgia rheumatica over the course of their disease. *Arthritis Rheum.* 2005;53:395-403.
6. Harris E, Tiganescu A, Tubeuf S, Mackie SL. The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy. *Curr Rheum Rep.* 2015;17:513.
7. Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. *Ann Rheum Dis.* 2016;75:952-7.
8. Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. *Ann Rheum Dis.* 2015;74:1799-807.
9. Duarte C, Ferreira RJ, Mackie SL, Kirwan JR, Pereira da Silva JA. Outcome Measures in Polymyalgia Rheumatica. A Systematic Review. *J Rheum.* 2015;42:2503-11.
10. Helliwell T, Brouwer E, Pease CT, Hughes R, Hill CL, Neill LM, et al. Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group. *J Rheum.* 2016;43:182-6.
11. Mackie SL, Arat S, da Silva J, Duarte C, Halliday S, Hughes R, et al. Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR. *J Rheum.* 2014;41:819-23.
12. Twohig H, Mitchell C, Mallen C, Adebajo A, Mathers N. "I suddenly felt I'd aged": a qualitative study of patient experiences of polymyalgia rheumatica (PMR). *Patient Educ Couns.* 2015;98:645-50.
13. Mackie SL, Hughes R, Walsh M, Day J, Newton M, Pease C, et al. "An impediment to living life": why and how should we measure stiffness in polymyalgia rheumatica? *PloS One.* 2015;10:e0126758.
14. Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. *Arthritis Rheum.* 2007;57:803-9.

15. Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. *Rheumatology (Oxford, England)*. 2010;49:716-22.
16. Boers M, Kirwan JR, Gossec L, Conaghan PG, D'Agostino MA, Bingham CO, 3rd, et al. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves Filter 2.0. *J Rheum* 2014;41:1025-30.
17. Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. *Ann Rheum Dis*. 2004;63:1279-83.
18. Boers MK, Tugwell P, Beaton D, Bingham CO, Conaghan P, D'Agostino M-A, et al. The OMERACT Handbook: OMERACT; 2016. Available from: http://www.omeract.org/pdf/OMERACT_Handbook.pdf.